Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors

•Cure rates are high for choriocarcinoma, however chemoresistant disease often leads to death.•High expression of PD-L1 suggests a role for checkpoint inhibitors in choriocarcinoma.•Pembrolizumab should be considered for salvage therapy for chemoresistant choriocarcinoma.

Saved in:
Bibliographic Details
Published inGynecologic oncology reports Vol. 34; p. 100625
Main Authors Clair, Kiran H., Gallegos, Nicolas, Bristow, Robert E.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.11.2020
Elsevier
Subjects
Case Report
Chemotherapy resistance
Choriocarcinoma
Gestational trophoblastic neoplasia
Immunotherapy
Choriocarcinoma
Chemotherapy resistance
Immunotherapy
Gestational trophoblastic neoplasia
Online AccessGet full text

Cover

More Information
Summary:•Cure rates are high for choriocarcinoma, however chemoresistant disease often leads to death.•High expression of PD-L1 suggests a role for checkpoint inhibitors in choriocarcinoma.•Pembrolizumab should be considered for salvage therapy for chemoresistant choriocarcinoma.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2020.100625